Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 59-73

  Brotherton, Julia M L ^a,c   Malloy, Michael ^a   Budd, Alison C ^b   Saville, Marion ^a   Drennan, Kelly T ^a   Gertig, Dorota M ^a,c  

^a VICTORIAN CYTOLOGY SERVICE   (Australia)

^b AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Human papillomavirus; Vaccination; Vaccine effectiveness

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; AGE; AUSTRALIA; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHILD; COHORT ANALYSIS; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SOCIAL STATUS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WOMEN'S HEALTH;

EID: 84947969189     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.05.005     Document Type: Review

References (34)

1. Brotherton J.M., Murray S.L., Hall M.A., Andrewartha L.K., Banks C.A., Meijer D., et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med. J. Aust. 2013, 199:614-617.
2. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjose S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131:2349-2359.
3. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
4. Brotherton J.M.L., Gertig D.M., Chappell G.A., Rowlands L., Saville M. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 year from the National HPV Vaccination Program Register. Commun. Dis. Intell. 2011, 35:197-201.
5. Brotherton J.M., Liu B., Donovan B., Kaldor J.M., Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey. Vaccine 2014, 32:592-597.
6. Watson M., Lynch J., D'Onise K., Brotherton J. Barriers to better three-dose coverage with HPV vaccination in school-based programs. Aust. N. Z. J. Public Health 2014, 38:91-92.
7. Brotherton J.M., Mullins R.M. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia. Cancer Epidemiol. 2012, 36:298-302.
8. Schiller J.T., Lowy D.R. Raising expectations for subunit vaccine. J. Infect. Dis. 2014, 211(9):1373-1375.
9. Gertig D.M., Brotherton J.M., Budd A.C., Drennan K., Chappell G., Saville A.M. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013, 11:227.
10. Budd A.C., Brotherton J.M., Gertig D.M., Chau T., Drennan K.T., Saville M. Cervical screening rates for women vaccinated against human papillomavirus. Med. J. Aust. 2014, 201:279-282.
11. AIHW, Cervical Screening in Australia 2011-2012, Cancer Series No. 82, AIHW Canberra Cat. No. CAN 79.
12. NHMRC Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities, (accessed 07.04.15). https://www.nhmrc.gov.au/guidelines-publications/wh39.
13. Chief Medical Officer, Guidelines, (accessed 07.04.15). http://www.health.gov.au/internet/immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/CMO-full-advice-hpv.pdf.
14. Korn E.L., Graubard B.I., Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am. J. Epidemiol. 1997, 145:72-80.
15. Australian Bureau of Statistics, 1216.0 - Australian Standard Geographical Classification (ASGC), 2006 Canberra (AUST), ABS, 2006.
16. Australian Bureau of Statistics, 2039.0 - An Introduction to Socio-Economic Indexes for Areas (SEIFA) 2006 [Internet], Canberra (AUST), ABS, 2008 [cited 2011 Jun 8],. http://www.abs.gov.au/ausstats/abs.nsf/mf/2039.0.
17. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
18. Crowe E., Pandeya N., Brotherton J.M., Dobson A.J., Kisely S., Lambert S.B., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ (Clin. Res. Ed.) 2014, 348:1458.
19. Smith L.M., Strumpf E.C., Kaufman J.S., Lofters A., Schwandt M., Lévesque LE. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts 2014, 135(5):e1131-e1140.
20. Herweijer E., Leval A., Ploner A., Eloranta S., Simard J.F., Dillner J., et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014, 311:597-603.
21. Baldur-Felskov B., Dehlendorff C., Junge J., Munk C., Kjaer S.K. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014, 25:915-922. Epub 2014 May 6. 10.1007/s10552-014-0392-4.
22. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J. Natl. Cancer Inst. 2014, 106. Epub 2014 Feb 19. 10.1093/jnci/djt460.
23. Blomberg M., Dehlendorff C., Sand C., Kjaer S.K. Dose-related differences in effectiveness of HPV vaccination against genital warts: a nationwide study of 550,000 young girls. Clin. Infect. Dis. 2015, May 5. pii: civ364. [Epub ahead of print].
24. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J. Natl. Cancer Inst. 2011, 103:1444-1451.
25. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev. Res. 2013, 6:1242-1250.
26. Pollock K.G., Kavanagh K., Potts A., Love J., Cuschieri K., Cubie H., Robertson C., Cruickshank M., Palmer T.J., Nicoll S., Donaghy M. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br. J. Cancer 2014, 111:1824-1830. Epub 2014 Sep 2. 10.1038/bjc.2014.479.
27. Brotherton J.M.L., Tabrizi S.N., Garland S.M. Does human papillomavirus type 16 or 18 prevalence in CIN3 lesions vary by age? An important issue for post vaccination surveillance. Future Microbiol. 2012, 7:193-199.
28. Castle P.E., Shaber R., LaMere B.J., Kinney W., Fetterman B., Poitras N., et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol. Biomark. Prev. 2011, 20:946-953.
29. Victorian Cervical Cytology Registry, Statistical Report 2013, VCS Inc., Melbourne, Australia, 2014, Available from: (accessed 18.05.15). http://www.vccr.org/data-research/statistical-reports/annual-statistical-reports.
30. Hariri S., Bennett N.M., Niccolai L.M., Schafer S., Park I.U., Bloch K.C., Unger E.R., Whitney E., Julian P., Scahill M.W., Abdullah N., Levine D., Johnson M.L., Steinau M., Markowitz L.E. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine 2015, 33:1608-1613. HPV-IMPACT Working Group, Epub 2015 Feb 11. 10.1016/j.vaccine.2015.01.084.
31. Barbaro B., Brotherton J.M.L. Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?. Aust. N. Z. J. Public Health 2014, 38(5):419-423.
32. Canfell K., Egger S., Velentzis L.S., Brown J.D., O'Connell D.L., Banks E., Sitas F. Factors related to vaccine uptake by young adult women in the catch-up phase of the National HPV Vaccination Program in Australia: results from an observational study. Vaccine 2015, 33:2387-2394. Epub 2015 Apr 3. 10.1016/j.vaccine.2015.01.024.
33. AIHW, Cervical Screening in Australia 2008-2009, Cancer Series No 61, AIHW Canberra Cat. No. CAN 57.
34. Brotherton J.M.L., Batchelor M., Winch K. Utility of reports and routine correspondence from the National HPV Vaccination Program Register. Med. J. Aust. 2013, 199:463.